Phase I drug-drug interaction study of Veltassa (patiromer) with Levothyroxine in healthy volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Feb 2017
At a glance
- Drugs Patiromer (Primary) ; Levothyroxine sodium
- Indications Hyperkalaemia
- Focus Adverse reactions
- Sponsors Relypsa
- 13 Feb 2017 According to a Relypsa media release, results from this study were published in the Journal of Cardiovascular Pharmacology and Therapeutics.
- 25 May 2016 According to a company media release, Relypsa submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa (patiromer) for oral suspension based on results of this and other Phase 1 drug-drug interaction studies in healthy volunteers.
- 29 Feb 2016 New trial record